A Longevity Industry Feature in Biopharma Dealmakers: Repair Biotechnologies, Deciduous Therapeutics, and More

In this study, a single treatment at the peak of disease resulted in the ablation of senescent cells in the lung and attenuation of key fibrotic and inflammatory markers, which ultimately resolved fibrosis. Deciduous Therapeutics has used computational assisted design to synthesise a suite of proprietary therapies that could be used in the clinic to re-activate tissue-resident iNKT cells. To date, the company's lead program has shown single-dose efficacy in resolving both metabolic and fibrotic diseases along with a favorable safety profile at doses significantly higher than the efficacious dose.
Source: Fight Aging! - Category: Research Authors: Tags: Longevity Industry Source Type: blogs